drugset / Trial / NCT00256451

Endophenotype for Alcohol Misuse in Healthy Minority Populations

NCT00256451

Phase 4 Completed 43 enrolled University of Pennsylvania
RandomizedCrossoverQuadruple-blindDiagnostic

Summary

The purpose of the study is to understand the relationship between what an individual inherited from their family (genetics), how they respond and feel after drinking alcohol, and how they respond to pre-treatment with naltrexone, a medication that blocks some of the effects of alcohol and is approved for the treatment of alcoholism. The investigators are conducting this study on those of African descent because there is almost no research focused on this group and the association with genetics. The investigators seek to enroll 40 people in the study. Participation will consist of 4 different alcohol challenge sessions in a cross over design. Each session will be separated by at least 10 days. In total, there will be four challenge sessions.

Timeline

Start
2005-11
Primary completion
2008-05
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Naltrexone Small molecule 50 mg

Indications

No indication recorded.